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Profiling Tumor-Associated Antibodies for Early Detection
of Non-small Cell Lung Cancer
Li Zhong, PhD,* Sarah P. Coe, BS,* Arnold J. Stromberg, PhD,† Nada H. Khattar, PhD,*
James R. Jett, MD,‡ and Edward A. Hirschowitz, MD*§
Background: A blood test for non-small cell lung cancer (NSCLC)
may be a valuable tool for use in a comprehensive lung cancer
screening strategy. Here we report the potential of autoantibody
profiling to detect early-stage and occult NSCLC.
Methods: T7-phage NSCLC cDNA libraries were screened with
patient plasma to identify phage-expressed proteins recognized by
tumor-associated antibodies. Two hundred twelve immunogenic
phage-expressed proteins, identified from 4000 clones, were statis-
tically ranked for their individual reactivity with 23 stage I cancer
patient and 23 risk-matched control samples. All 46 samples were
used as a training set to define a combination of markers that were
best able to distinguish patient from control samples; this set of
classifiers was then examined using leave-one-out cross-validation.
Markers were then used to predict probability of disease in 102
samples from the Mayo Clinic CT Screening Trial (six prevalence
cancer samples, 40 drawn 1 to 5 years before diagnosis, and 56
risk-matched controls).
Results:Measurements of the five most predictive antibody markers
in 46 cases and controls were combined in a logistic regression
model that yielded area under the receiver operating characteristics
curve of 0.99; leave-one-out validation achieved 91.3% sensitivity
and 91.3% specificity. In testing this marker set with samples from
the Mayo Clinic Lung Screening Trial, we correctly predicted six of
six prevalence cancers, 32 of 40 cancers from samples drawn 1 to 5
years before radiographic detection on incidence screening, and 49
of 56 risk-matched controls.
Conclusions: Antibody profiling may be a useful tool for early
detection of NSCLC.
Key Words: Lung cancer, Early detection, Tumor-associated auto-
antibodies, Phage display, Biomarkers, Protein microarray.
(J Thorac Oncol. 2006;1: 513–519)
Lung cancer screening initiatives are based on the knowl-edge that only 25% of non-small cell lung cancer
(NSCLC) is diagnosed at an early stage when curative sur-
gical resection is still possible.1 The use of solely age and
smoking history as selection criteria in population-based
computed tomography (CT) screening trials offers a low yield
of cancer detection at significant cost.2–7 Moreover, the rou-
tine identification of indeterminate pulmonary nodules during
CT screening often requires additional workup, magnifying
the cost and adding potential morbidity from related inter-
ventional diagnostic procedures.
We have developed an assay for detecting NSCLC that
could be a clinically valuable tool for early diagnosis, espe-
cially when used in concert with radiographic imaging and
other screening modalities. In a previous report, we described
the development of a diagnostic assay using tumor associat-
ed-antibodies as markers for NSCLC.8 Specifically, fluores-
cent microarray technology was adapted to the task of iden-
tifying phage-expressed NSCLC-associated proteins, used in
turn to measure corresponding antibodies in blood. Combined
measures of antibody reactivity to an arrayed panel of phage-
expressed proteins were highly predictive of advanced stage
NSCLC.8 Anticipating that antibody profiles may focus
screening efforts by defining a population with high proba-
bility of disease, we determined the predictive accuracy of
this approach for early-stage NSCLC and explored the po-
tential to predict disease before a cancer could be detected on
CT scan. We used 23 stage I NSCLC samples and 23
risk-matched controls to choose a set of markers, build a
weighted statistical model, and determine the assay’s predic-
tive accuracy for early-stage NSCLC. Using an optimal
combination of five markers determined above, we then
assayed 102 samples from the Mayo Clinic Lung Screening
Trial that included 56 noncancer samples, six prevalence
cancers, and 40 cancer samples drawn 1 to 5 years before
detection on incidence screening (Fig. 1).9
MATERIALS AND METHODS
Human Subjects
After informed consent, plasma samples were obtained
from individuals with histology confirmed NSCLC at the
University of Kentucky and Lexington Veterans Administra-
tion Medical Center. Noncancer controls were randomly
chosen from 1520 subjects participating in the Mayo Clinic
Lung Screening Trial. Briefly, individuals were eligible for
*Department of Internal Medicine, Division of Pulmonary and Critical Care
Medicine and †Department of Statistics, University of Kentucky, Lex-
ington, KY; ‡Division of Pulmonary and Critical Care Medicine, Mayo
Clinic, Rochester, MN; and §Lexington Veteran’s Administration Med-
ical Center, Lexington, KY.
Address for correspondence: Li Zhong, Ph.D., Division of Pulmonary and
Critical Care Medicine, University of Kentucky, Chandler Medical Cen-
ter, K528 Kentucky Clinic, 740 S. Limestone, Lexington, KY 40536.
E-mail: lzhon2@uky.edu
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0106-0513
Journal of Thoracic Oncology • Volume 1, Number 6, July 2006 513
the CT screening trial with a minimum 20 pack-year smoking
history, age 50 to 75, and no other malignancy within 5 years
of study entry.4,9 In addition to noncancer samples from the
Mayo Lung Screening Trial, six stage I prevalence NSCLC
samples and 40 prediagnosis samples were available for
analysis. Prediagnosis samples were drawn at study entry
from subjects diagnosed with NSCLC incidence cancers on
screening CT 1 to 5 years after sample donation. Serial blood
samples were not drawn on these patients. Patient character-
istics are shown in Table 1.
Phage Libraries, Biopanning, and High-
Throughput Screening
One T7-phage NSCLC cDNA library was purchased
(Novagen, Madison, WI) and a second was constructed from
the adenocarcinoma cell line NCI-1650 using Novagen’s
OrientExpress cDNA Synthesis and Cloning systems.8 The
libraries were biopanned with pooled plasma from 5 NSCLC
patients (stage II–IV) and normal healthy donors to enrich the
population of phage-expressed proteins recognized by tumor-
associated antibodies as previously described.8 Phage lysates
from the biopanned libraries were amplified and grown on
LB-agar plates covered with 6% agarose for isolating indi-
vidual phages. A colony-picking robot (Genetic QPix 2,
Hampshire, UK) was used to pick 4000 individual colonies
(2000 per library). The picked phages were reamplified in
96-well plates, grown until bacterial lysis, centrifuged, and 5
nL of phage containing supernatant from each well was then
robotically spotted in duplicate onto FAST array slides
(Schleicher and Schuell, Keene, NH) using an Affymetrix
417 Arrayer (Affymetrix, Santa Clara, CA).
Five individual NSCLC (stage III/IV) patient plasma
samples not used in the biopan were used to identify immu-
nogenic phage–expressed proteins from the screening slides
of each library. Rabbit anti-T7 primary antibody (Jackson
Immuno-Research, West Grove, PA) was used to detect T7
capsid proteins as a control for the amount of phage. Both
plasma samples and anti-T7 antibodies were diluted 1:3000
with 1TBS plus 0.1% Tween-20 (TBST) and incubated
with the screening slides for 1 hour at room temperature.
Slides were washed and then probed with Cy5-labeled anti-
human and Cy3-labeled anti-rabbit secondary antibodies
FIGURE 1. Experimental design. The flowchart delineates
sample usage and designation to training and testing
groups, as well as the statistical results of sequential
evaluation.
TABLE 1. Characteristics of the Patient Samplesa
No. of cases Age, y Sex No. of smokers
No. of
controlsa Age, y Sex No. of smokers
Sample set A
Ad  7
Sq  8
NSCLCb  8
Total  23
51–79 (avg 65.1) Male (17),
female (6)
Active (20),
former (3),
never (0)
23 50–76 (avg 62.5) Male (11),
female (12)
Active (12),
former (11),
never (0)
Sample set B
Prediagnosisc
0 y  6
1 y  12
2 y  11
3 y  11
4 y  4
5 y  2
Total  46
51–80 (avg 63.6) Male (20),
female (26)
Active (24),
former (22),
never (0)
56 50–85 (avg 63.1) Male (26),
female (30)
Active (24),
former (22),
never (0)
Sample set A: used for marker selection, statistical modeling, and accuracy prediction. All cancers were stage IA or IB non-small cell lung cancer. Sample set B: used for
independent validation. a Of the controls, 34 of 79 had benign nodules (n  11 sample set A, n  22 sample set B). b Undifferentiated non-small cell lung cancer or inadequate tissue
to characterize histology. c Adenocarcinoma, n 23; bronchoalveolar cell carcinomas, n 7; Squamous cell carcinoma, n 13; non-small cell lung cancer, n 5. Prevalence cancers
(0 year) stage I  6; incidence cancers (years 1–5) stage I  25; stage II  7; stage III  6; stage IV  2.
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(Jackson Immuno-Research; 1:4000 each antibody in TBST)
together for 1 hour at room temperature. Slides were washed
again and then scanned using an Affymetrix 428 scanner.
Images were analyzed using GenePix 5.0 software (Axon
Instruments, Union City, CA). Phages with a Cy5/Cy3 signal
ratio greater than 2 SDs from a linear regression were
selected as candidates for use on a “diagnostic chip.”
Diagnostic Chip Design and Antibody
Measurement
Two hundred twelve immunoreactive phages identified
in the high-throughput screening above plus 120 “empty” T7
phages were combined, reamplified, and spotted in duplicate
onto FAST slides as single diagnostic chips. Replicate chips
were used to assay 23 stage I NSCLC and 23 risk-matched
plasma samples using the protocol described for screening
above. The median of Cy5 signal was normalized to the
median of Cy3 signal (Cy5/Cy3 signal ratio) as the measure-
ment of human antibody against a unique phage-expressed
protein. Measurements were further normalized by subtract-
ing background reactivity of plasma against empty T7 phage
and dividing by the median of the T7 signal [(CY5/Cy3 of
phage Cy5/Cy3 of T7)/Cy5/Cy3 of T7]. This methodology is
quantitative, reproducible, and compensates for chip-to-chip
variability, allowing comparison between samples.8
Statistical Analysis
The normalized Cy5/Cy3 ratio for each of the 212
phage-expressed proteins was independently analyzed for
statistically significant differences between 23 patients and 23
control samples by t test using JMP statistical software (SAS,
Inc., Cary, NC). The most predictive individual markers were
checked for redundancy by polymerase chain reaction ampli-
fication using commercial T7-phage vector primers (Nova-
gen) as previously described.8 Using a panel of nonredundant
phage-expressed proteins, logistic regression analysis was
performed to predict the probability that a sample was from
an NSCLC patient. All 46 samples were used to build up
classifiers that were able to distinguish patients from normal
samples using individual or a combination of markers. Re-
ceiver operating characteristics (ROC) curves were generated
to compare the predictive sensitivity, specificity, and the area
under the curve (AUC). The classifiers were then examined
using leave-one-out cross-validation within all the 46 sam-
ples.10 This set of classifiers was then used to predict the
probability of disease in an independent set of 102 cases and
risk-matched controls from Mayo Clinic Lung Screening
Trial (Fig. 1). Relative effects of smoking and other nonma-
lignant lung disease were also assessed.
Sequence Identification of Phage-Expressed
Proteins
When possible, phage identity was made based on
significant nucleotide and translated nucleotide matches (bit
score, e value, and percentage of sequence match) with a
single gene in the GenBank database using BLASTN and
BLASTX search engines.
RESULTS
High Throughput Screening and Marker
Selection
The diagnostic chip, composed of 212 immunoreactive
phage-expressed proteins plus controls, was derived from two
T7-phage NSCLC cDNA libraries that were screened with
NSCLC patient plasmas. Because anomalous proteins are
generally accumulated and not lost during tumor progression,
screening was performed with stage II to IV samples, ratio-
nally assuming that more advanced stage samples would
provide a broad range and robust source of tumor-associated
antibodies generated in the early life of the tumor.11 The
relative predictive value of each phage clone for early-stage
lung cancer was suggested by statistical differences in the
mean normalized signal from 23 early-stage patients com-
pared to 23 high-risk controls (Fig. 2). Forty-nine of these
212 candidate markers showed statistically significant differ-
ences between cases and control (p  0.05), 33 of which had
p  0.01; 13 markers offering the highest level of discrimi-
nation (p  1.9  1011 to p  0.00007) were further
evaluated. Sequence analysis revealed several duplicates and
triplicates among those 13 phage-expressed “capture” pro-
teins. Redundant clones were eliminated, and the antibody
reactivity to the five most reactive unique phage-expressed
proteins was analyzed individually as well as a combination
to achieve the most optimal predictive accuracy (maximal
discrimination among these 46 samples, Fig. 2).
Statistical Modeling and Assay Prediction
Accuracy
Logistic regression was used to calculate the sensitivity
and specificity of individual and combinations of multiple
markers. The AUC ROC curve for each individual marker,
achieved by assaying all the 46 samples to estimate predictive
ability, ranged from 0.74 to 0.95; combinations of five mark-
ers indicated significant ability to distinguish early-stage
patient samples from risk-matched controls (AUC  0.99)
(Fig. 2). The computed sensitivity and specificity using leave-
one-out cross-validation were 91.3% and 91.3%, respectively
(Table 2). We were unable to accurately distinguish histo-
logic type of tumor in this sample set.
A sample cohort from the Mayo Clinic CT Screening
trial that included 46 samples drawn 0 to 5 years before
diagnosis (six prevalence cancers and 40 precancer samples)
and 56 risk-matched samples from the screened population
was then analyzed as an independent data set (Fig. 1). We
were able to accurately classify 49 of 56 noncancer samples,
six of six cancer samples drawn at the time of radiographic
detection on a screening CT, nine of 12 samples drawn 1 year
before diagnosis, eight of 11 drawn 2 years before, 10 of 11
drawn 3 years before, four of four drawn 4 years before
diagnosis, and one of two drawn 5 years before diagnosis,
corresponding to 87.5% specificity and 82.6% sensitivity
(Table 3). Three of the eight precancer samples incorrectly
classified were bronchoalveolar cell histology.
In the testing sets, we correctly classified six of six
noncancer controls with a clinical diagnosis of chronic ob-
structive pulmonary disease, one individual with sarcoidosis,
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and one individual with an interval diagnosis of breast cancer.
In the latter independent testing set, two individuals with
localized prostate cancer were also correctly classified as
normal. One individual with a previous diagnosis of breast
cancer (5 years before) was classified as noncancer, but a
second was classified as cancer. Thirty-four of 79 noncancer
subjects had benign nodules detected on screening CT scans
(Table 1). History of active versus former smoking did not
appear to affect the predictive accuracy of the test. There was
also no association of assay sensitivity with time to diagnosis.
Sequence Analysis of Phage-Expressed Proteins
Although the identity of the phage-expressed proteins is
not critical for use in a diagnostic assay, the nucleotide
sequences of the five predictive phage-expressed proteins
were compared to the GenBank database to obtain possible
identities and also compared to those that were highly pre-
dictive of advanced stage lung cancer.8 Nucleotide sequences
obtained from the five clones used in the final predictive
model showed great homology to paxillin, SEC15L2, BAC
clone RP11-499F19, XRCC5, and MALAT1. The first three
were identified in previous work as immunoreactive with
plasma from patients with advanced-stage lung cancers.8
XRCC5 is a DNA repair gene overexpressed in some lung
cancers.12 Anomalous activity and aberrant expression of
paxillin, a focal adhesion protein, has been associated with an
aggressive metastatic phenotype in lung cancer and other
malignancies.13–17 SEC15L2 is an intracellular trafficking
protein that does not have any known malignant association,
although its physiologic function suggests that it could have
a role in the malignant phenotype.18 MALAT1 is a regulatory
ncRNA known to be anomalously expressed in lung can-
cer.19,20 The BAC clone has no known associated protein
function.
DISCUSSION
Although blood tests for lung cancer have multiple
uses, specific application to early diagnosis is highly compel-
ling for its potential impact on disease outcomes.21,22 In this
report, we explore the potential of autoantibody profiling as a
tool to complement radiographic screening for lung cancer.
Serial CT screening is highly sensitive for lung cancer, but
criticisms arise from the high cost and the low 64% specific-
ity.2–7,23,24 Moreover, the routine identification of indetermi-
nate pulmonary nodules during radiographic imaging frequently
leads to expensive workup and potentially harmful intervention,
including major surgery.24 Currently, age and smoking history
are the only two risk factors that have been used as selection
criteria by the large screening studies, and so far an appro-
priate subpopulation has not been defined.2–7,23,24 A blood test
that could detect radiographically apparent cancers (0.5
FIGURE 2. Statistical analysis of the five individual markers in the training group. A: Dot plots show the reactivity of 23 stage
I non-small cell lung cancer (NSCLC) patients and 23 risk-matched control samples to phage-expressed proteins L1919,
L1896, G2004, G1954, and G1689. The horizontal lines within the plots indicate the mean for each group. B: The corre-
sponding receiver operating characteristics curves and the value of the area under the curve (AUC) are shown for each indi-
vidual marker.
TABLE 2. Logistic Regression and Leave-One-Out Validation
in Training Group
Phage clone
Traininga Validationb
AUC
Specificity,
%
Sensitivity,
%
Specificity,
%
Sensitivity,
%
L1919 0.85 82.6 78.3 82.6 60.9
L1896 0.95 87 87 87 87
G2004 0.80 82.6 65.2 82.6 65.2
G1954 0.74 82.6 87 73.9 69.6
G1689 0.82 82.6 65.2 82.6 65.2
5 Combined 0.99 100 95.7 91.3 91.3
AUC, area under the receiver operating characteristics curve. aTraining Set con-
sisted of 23 high-risk normal and 23 NSCLC stage-one patient samples. bLeave-one-out
validation: prediction of single sample based on 45 cases and controls.
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cm) and occult disease or premalignancy (below the limit of
radiographic detection) would define individuals for whom
screening is most warranted.
We have previously described methodology to effi-
ciently screen T7-phage NSCLC cDNA libraries for multiple
phage-expressed proteins recognized by antibodies in
NSCLC patient plasma. We showed that these proteins could
be displayed in an array fashion and used to measure multiple
antibodies simultaneously, the combination of which has
excellent ability to discriminate advanced stage NSCLC from
control samples.8 With interest in improving early detection
for lung cancer, we now investigate the ability of antibody
profiling to distinguish stage I lung cancer and occult disease
from risk-matched control samples.
We statistically identified a five-antibody marker com-
bination from an arrayed panel of 212 immunoreactive
phage-expressed proteins that achieved excellent discrimina-
tion between 23 stage I NSCLC and 23 risk-matched control
samples. The 91% predictive accuracy obtained in a leave-
one-out validation of these 46 samples is consistent with
similarly high levels achieved with autoantibody profiling for
prostate cancer recently described by Wang et al.25 The
potential of this approach to complement radiographic
screening for lung cancer can be recognized in subsequent
validation where combined measures of these five antibody
markers correctly predicted 49 of 56 noncancer samples from
the Mayo Clinic Lung Screening Trial, as well as six of six
prevalence cancers and 32 of 40 incidence cancers from
blood drawn 1 to 5 years before radiographic detection,
corresponding to 87.5% specificity and 82.6% sensitivity.
Of the 40 pre-NSCLC diagnosis samples from the
Mayo Screening trial, it is impossible to determine which
were from individuals with established (occult) cancers and
which were from individuals with dysplastic lesions yet to
undergo malignant transformation. Based on doubling times,
a lung cancer can be present 3 to 5 years before reaching the
conventional size limits of radiographic detection (0.5
mm).22,23,26,27 We also know that premalignant lesions and
associated molecular abnormalities can be present for de-
cades before malignant transformation.22,26–30 It is therefore
not unexpected that premalignant lesions can be distinguished
from normal epithelium by histologic, genetic, and proteomic
analysis,26–33 and thus not surprising that autoantibodies are
generated to anomalous proteins. Importantly, three of these
five early-stage markers also had high predictive value in
advanced cancer,8 consistent with our knowledge that anom-
alous protein expression is often conserved during tumor
progression and supporting the association of these markers
with established NSCLC.8,11,26,27 Notably, none of the mark-
ers, alone or in combination, showed specificity for a unique
histologic subtype of NSCLC, although three of the seven
BACs in the case sample cohort were incorrectly classified as
normal (three of eight precancer samples misclassified). With
the exception of BAC, an indolent cancer that may not induce
as robust an antibody response as other histologic types of
NSCLC, we assume that our markers are variably expressed
in malignant/premalignant lesions of the lung. The presence
of benign pulmonary nodules and other nonmalignant lung
disease (e.g., obstructive pulmonary disease) did not appear
to alter marker specificity.
The specific role of these five proteins in tumor devel-
opment or progression is unknown. Further investigation
could reveal pathophysiologic importance, although it should
be emphasized that an extended nucleotide homology of the
phage-expressed protein to a known sequence may be entirely
irrelevant to the epitope recognized by the autoantibody. Any
of these five phage-expressed proteins (100–175 amino acids
in length) may include short stretches of amino acids belong-
ing to different antigenic parent proteins, even though the
complete sequence does not bear significant homology to that
protein, so-called mimotopes.25 Although we have found that
a statistical combination of these five proteins provides a very
high level of discrimination, we have not exhaustively
screened these tumor libraries for immunogenic proteins.
TABLE 3. Predictive Accuracy Using Five Combined Biomarkersa in Testing Set
Noncancer high risk
Cancer (n  46)
Years to cancer
0 1 2 3 4 5
No. classified correctly/total 49/56b 6/6 9/12c 8/11c 10/11c 4/4 1/2c
Histology (no.)
Adeno carcinoma
Squamous
NSCLC
Bronchoalveolar
4
2
0
0
7
3
1
1
4
4
3
0
3
3
0
5
3
1
0
0
0
0
1
1
Stage (no.)
I
II
III
IV
6
0
0
0
9
2
1
0
7
1
1
2
9
1
1
0
1
2
1
0
2
0
0
0
aMarkers used in this validation were the same five used in the training group. bIncluded 22 of 56 with benign pulmonary nodules, eight individuals with obstructive lung disease,
two individuals with localized prostate cancer, and two individuals with remote diagnosis of breast cancer. cIncorrectly classified: 1 year, one stage I bronchoalveolar carcinoma; one
stage I adenocarcinoma; one stage I squamous cell carcinoma; 2 years, two stage I squamous cell carcinomas; one stage I undifferentiated non-small cell lung cancer; 3 years, one
stage I bronchoalveolar carcinoma; 5 years, one stage I bronchoalveolar carcinoma.
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Further, we have used highly stringent statistical methods for
selecting and combining antibody measures. Importantly, if
additional predictive accuracy is required for clinical imple-
mentation, the methods described here allow us to incorpo-
rate additional markers in a single assay to accommodate
disease heterogeneity and also allow further adjustment of
sensitivity and specificity by statistically weighting various
markers.
Although an ideal screening test would have high
specificity and sensitivity that approaches 100%, perfect
prediction is not expected.21 Of some potential relevance for
use of this specific five-antibody marker set for screening is
that the eight of 40 occult cancers were incorrectly classified
as normal. Similar to screening for prostate cancer, breast,
and colon cancer (PSA and digital rectal examinations, mam-
mograms and clinical breast examinations, stool guiac and
colonoscopy), no single test is likely to be a practical and
comprehensive independent screening modality for lung can-
cer screening. In context, the initial report of the Mayo Clinic
Lung Screening Trial by Swensen et al.34 described 35 cases
of NSCLC diagnosed by CT alone, one NSCLC detected by
sputum cytologic examination alone, and one stage IV
NSCLC clinically detected between annual screening scans,
corresponding to a 94.5% sensitivity of CT scanning alone.
Further, retrospective review after the first annual incidence
scan revealed that small pulmonary nodules were missed on
26% of the prevalence scans, consistent with significant
false-negative rates reported in other CT screening trials.34,35
The diameter of the retrospectively identified nodules was4
mm in 231 participants (62% of those 375 participants), 4 to
7 mm in 137 (37%), and 8 to 20 mm in six (2%). As such, the
82.6% sensitivity of autoantibody profiling for NSCLC com-
pares quite favorably to that of CT screening alone, by
comparison may perform especially well for small tumors,
and represents an unparalleled advance in the detection of
occult disease. Moreover, the 87.5% specificity of this assay
well exceeds that of CT scanning, which becomes increas-
ingly more important as the percentage of benign pulmonary
nodules increases in the at-risk population, rising to levels of
69% of participants in the Mayo Clinic Screening Trial.9,22
The data do, however, suggest these markers may not be very
sensitive for the BAC histologic subtype.
These data suggest that antibody profiling could be a
powerful tool for early detection when incorporated into a
comprehensive screening strategy.26,35,36 Admittedly, imple-
mentation of autoantibody profiling as a screening tool will
require rigorous validation. Problematically, the number of
clinical blood samples from individuals with occult disease or
premalignancy available from investigational screening trials
is exceedingly small. Further validation of these results may
best be accomplished with analysis of archived samples from
other completed or ongoing CT screening trials or with
samples collected in studies investigating autofluorescence
bronchoscopy. It will also be important to more fully evaluate
the specificity of antibody signatures in patients with a variety
of benign lung disease and autoimmune disease and to define
the specificity for lung versus other cancers.36 It is also
rational to test these markers with small-cell lung cancer to
determine the predictive accuracy for this lung cancer variant.
Although not specifically explored in this study, application
to the closely related clinical problem of distinguishing be-
nign from malignant nodules identified on CT screening is
also logical. The ultimate validation of antibody profiling will
be accomplished in a prospective lung cancer screening trial
that will then be followed by careful population-based anal-
ysis to define an optimal screening approach for lung can-
cer.36 Although a blood test for lung cancer could signifi-
cantly alter the current screening paradigm, the impact on
disease-specific mortality will need to be proven.
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